

Alpha-emitting therapeutic radiopharmaceuticals: nonclinical studies prior to initiating a human study, dose selection, and impact of impurities

> Haleh Saber, PhD Deputy Director Division of Hematology Oncology Toxicology (DHOT) Office of Oncologic Diseases/ CDER/ FDA

Abbreviations



- BSA: body surface area
- BW: body weight
- D: radiation absorbed dose
- CV: cardiovascular
- CNS: central nervous system
- FIH: first-in-human
- %ID: percent of injected dose (percent of injected activity)
- LET: linear energy transfer
- mAb: monoclonal antibody
- PK: pharmacokinetics
- RBE: relative biological effectiveness
- T_{1/2}: half-life
 - Te: effective half-life

Overview of this presentation



- Nonclinical studies in support of FIH studies
 - Described in the FDA Guidance:

Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations

https://www.regulations.gov/docket?D=FDA-2018-D-1772

- FIH dose selection
 - Described in the FDA guidance (see above)
- Alpha-emitting radionuclides

Nonclinical studies in support of FIH studies



- Pharmacology
 - Proof of concept
 - Could be used to determine the maximum tolerated radiation dose in animals
- Safety pharmacology (CNS, CV, respiratory)
 - Stand-alone studies usually not needed
 - Assessment through:
 - Biodistribution study (information re: radiation)
 - General toxicology (information re: cold pharmaceutical)



Nonclinical studies in support of FIH studies (cont'd)

- Animal biodistribution, to aid in:
 - FIH dose selection (for human dosimetry)
 - Assessing toxicities from radiation, based on distribution of radiation and the knowledge of organ-specific radiation toxicities. Toxicity endpoints (e.g. nonsacrificial) may be added.
- A toxicology study, to assess:
 - *Ligand related effects
 - A toxicology study to assess radiation-induced toxicities usually not needed


* Targeting or chelating agent

Nonclinical studies in support of FIH studies: Animal biodistribution



Needed to support human dosimetry. Usually:

- Single dose administration
- One species
- Activity over time in organs of animals: *total # of decays*
 - Can be used to estimate time-integrated activity in human organs \rightarrow estimate absorbed doses in human organs




Use human dosimetry data to select the therapeutic dose of the radiopharmaceutical

Use of theranostic pairs (assume no relevant clinical data)



- The clinical candidate is not appropriate for imaging/ dosimetry in animals or humans? alpha-or beta-emitting
- The product used in animals cannot be used for imaging/ dosimetry in humans?





Animal biodistribution and dosimetry (cont'd)


- Estimates at best
- May underpredict effects in humans
 - Biological targeting moiety may be immunogenic in animals
 - higher clearance \rightarrow reduced # of transitions

From the guidance

"When there is experience with the radionuclide or the ligand components of the radiopharmaceutical being developed, the nonclinical program can be abbreviated as needed, and the FIH dose can be based on clinical data, as appropriate."

Abbreviated nonclinical program: example





9

FIH dose selection



(in the absence of relevant clinical data)

 Mass dose (cold pharmaceutical): Follow recommendations in ICH S9 guidance. May not be essential (e.g. mcg doses)

Radiation dose

- Selection of the activity to be administered (Bq or Ci) per BW or BSA for patient dosimetry should be based on
 - the animal biodistribution and dosimetry data,
 - the estimated absorbed radiation doses in human organs, and
 - tolerance of human organs to radiation
- For organ tolerance in patients: can use literature on external radiation therapy as a starting point.
 - May use an RBE of 5 for alpha-emitting radiopharmaceuticals

Alpha-emitting radiopharmaceuticals



Pros	Cons
 High potency: DNA double strand break A high linear energy transfer (LET) that increases the radiation dose in tumors High relative biological effectiveness (RBE) 	Due to the short range, the resulting dose distributions in tumors can be nonuniform
A short/ moderate pathlength (50–100 μm) range may potentially reduce injury to healthy tissues surrounding the tumor	Imaging and dosimetry could be challenging
May be suitable for micrometastases	After emission, daughter nuclides experience a recoil energy, resulting in decoupling from the chemical bond and redistribution
	Daughter radionuclides resulting in additional doses
	The high LET may result in injury to healthy tissues when/if the radionuclides detach and redistribute



Alpha emitting radiopharmaceuticals :

essential properties in drug development

- Ligand properties: Reduce effects related to recoil and redistribution of the radionuclides
 - fast delivery to the tumor
 - internalization
 - extended tumor retention

Daughter radioisotopes recoiling from an alpha-emitting parent (breaching the chemical bonds) would travel a relatively short distance

- Physical T_{1/2}: not too short (potent cytotoxic effect and ability to deliver desired doses post manufacturing). Not too long (patient safety; environmental exposure)
- Imaging capabilities



Alpha particle: Imaging, biodistribution/ dosimetry


- Dissecting organs and using scintillation counters
- Theranostic strategy
- Imageable signals in a decay chain (approach has been used for ²²³Ra)
 - Conventional gamma cameras, single-photon emission computed tomography (SPECT), and
 - positron emission tomography (PET)
- Imaging technology for the ex vivo detection of α -particles in tissues

https://jnm.snmjournals.org/content/51/10/1616.long https://jnm.snmjournals.org/content/55/supplement_1/50 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554362/

Why ²²⁵AC?




- Availability of clinical data with ²²⁵Ac
- Availability of clinical data with ²¹³Bi ?



https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237921

PubMed advanced search (June 2021)

- Keywords
 - (actinium) AND (clinical)--- 211 hits
 - (actinium-225) AND (clinical)--- 75 hits
 - (actinium-225) AND (cancer)--- 121 hits





Why ²²⁵AC (cont'd)

- Half-life not too short or too long
- Nonclinical and clinical data reported in published articles
- While ²²⁵AC does not have its own imageable emission, several daughter radionuclides have gamma emissions (e.g. ²¹³Bi)

Case study



- Clinical candidate was ²²⁵Ac-chelator-mAb (²²⁵Ac-XX)
- Publications cited by the Sponsor for use of ¹¹¹In as a theranostic pair of ²²⁵Ac. The tumor and normal organ biodistribution of ²²⁵Ac-labeled antibodies was similar to the ¹¹¹In-labeled antibodies
- Limited human dosimetry data was also available with ¹¹¹In-XX (same indication)
- The organ specific radiation dosimetry estimates of ²²⁵Ac-XX in animals consistent with the results of the clinical study with ¹¹¹In-XX.

The radiation starting dose of ²²⁵Ac-XX was determined based on the results from the clinical study with ¹¹¹In-XX

Examples of articles on ¹¹¹In and ²²⁵Ac: <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295045/</u> <u>https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.9b00542</u>



²²⁵Ac with ²²⁷Ac impurity

- The amount of generator-produced ²²⁵Ac (Oak Ridge National Laboratory, managed by the DOE Isotope Program) is limited. Alternative sources of ²²⁵Ac may be needed to support the growing clinical demand.
- To increase the supply of ²²⁵Ac, the DOE Isotope Program has developed an alternative method to produce a ²²⁵Ac; accelerator-produced ²²⁵Ac.
 - Results in co-production of ²²⁷Ac, at activity levels of 0.1 to 0.2% relative to the activity of ²²⁵Ac at production (proposed levels by sponsors could be higher at the time of use).
 - ²²⁵Ac and ²²⁷Ac cannot be chemically separated.
 - $^{227}Ac has a long half-life of 21.8 years (²²⁷Ac → ²²⁷Th; mostly beta-emitting).$ <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237921/pdf/CRP-11-200.pdf</u>
- Safety concerns:
 - Patient level
 - Environmental/ waste
 - Safe handling/ disposal of unused materials

Safety concerns: patient-level



- ²²⁷Ac remaining with the ligand/ stability?
 - To indicate that ²²⁷Ac will not dissociate from the product before removal by biological processes. If data indicates that ²²⁷Ac remains with the ligand, then ²²⁷Ac may be eliminated from the body with the elimination of the ligand (consistent with the effective half-life, Te).
- When conducting biodistribution/dosimetry in animals, take into consideration absorbed doses from ²²⁵AC, ²²⁷Ac, and daughter decays
 - If any decay is not included in the calculation (e.g. short half-life), indicate this in the submission and the rationale
- Switching to accelerator-produced ²²⁵Ac after animal studies and cohorts of human studies completed? May consider the following approaches:
 - See the first bullet
 - Modeling: may use the worst-case scenario of ²²⁷Ac impurity separating and distributing
 - An abbreviated animal dosimetry and excretion/mass balance study



Questions for the FDA review team?

You can ask for a meeting







Challenges to Safety Assessments in Early Phase Clinical Trials for Radiopharmaceuticals

Mitchell S. Anscher, MD Medical Officer CDER/OND/DO1



Disclosures

- Nothing to disclose
- I will not be speaking about off-label use of drugs or devices

Radiopharmaceutical Therapy-the Good, the Bad and the Ugly



- Good
 - Targeted
 - High dose to tumor
 - Low energy (rapid fall off)
 - Combine imaging and therapy
- Bad
 - Target not necessarily tumor-specific (PSMA)
 - Depth of penetration may be too low (alphas) or too high (gammas)
 - Can't always image, correlation between imaging and therapy
- Ugly
 - Dosimetry combines challenges of pharmacology and radiotherapy
 - Explosion in new applications
 - Lack long-term follow-up data to establish true tolerance doses






Dosimetry of Radiopharmaceuticals vs External Beam Radiation

- Limited dose input data (few sample points)
- Non-uniform dose distribution
- Lower/variable dose rates
- Models/software designed for low exposure imaging studies
 - Assume uniform dose distribution in a tissue
 - Do not provide dose gradients at tissue boundaries
 - Do not provide direct tumor dose correlations
- Tolerance dose estimates based on conventionally fractionated external beam radiation
 - Evidence suggests tolerances doses are very different
 - Acute hematologic toxicity may be more of an issue for radiopharmaceuticals

4 R's of Radiobiology




Hall, EJ & Brenner, DJ. IJROBP 21: 1403, 1991; Hall EJ. Radiobiology for The Radiologist, 1994, p136

FDA



Potential Advantages of α -Particles

- Densely ionizing vs photons, protons, β-particles
 - High linear energy transfer (LET)
 - Nearly ideal LET, as the average separation between ionizing events is roughly equal to the diameter of a DNA double helix (~2nm)
- The 4 R's don't apply
 - No repair of sublethal damage
 - No cell cycle redistribution
 - No enhanced effect of oxygen
 - No repopulation
 - No dose rate effect
 - Short path length
- Therefore, much higher relative biological effect (RBE) vs photons, protons, β-particles



Hill, RP and Bristow, RG. chapter 16: Tumor and Normal Tissue Response to Radiotherapy. In: The Basic Science of Oncology, ed: Tannock, Hill, Bristow and Harrington, 5th edition



What Types of Radiation Injury Determine the Therapeutic Ratio

- Usually, it's the late effects
 - Traditionally defined as those persisting or occurring >90 days after treatment
 - RT injury is basically dysregulated wound healing
 - Process begins immediately with the first exposure
 - May take years to develop
 - Wide individual variation, which is not always well-predicted
 - Limited therapeutic options if late effects develop
 - Prevention is key
 - Requires accurate knowledge of RT dose distributions at the individual patient level for every administration



What Influences Therapeutic Ratio?

- Patient factors
 - Underlying illnesses (diabetes, chronic lung disease, heart disease, chronic liver disease, collagen-vascular diseases, inflammatory bowel disease)
 - Lifestyle issues (smoking)
 - Genetics (known and unknown)
 - Epigenetics
- Treatment factors (radiation)
 - Total dose, dose/fraction, dose rate, modality (EBRT, brachy), volume of normal tissue
- Other treatments
 - Systemic agents, surgery, OTC stuff patients don't tell you about
- Tumor factors
 - Histology
 - Genetics
 - Epigenetics



What Influences Can We Control?

- Patient factors
 - Underlying illnesses (diabetes, chronic lung disease, heart disease, chronic liver disease, collagen-vascular diseases, inflammatory bowel disease)
 - Lifestyle issues (smoking)
 - Genetics (known and unknown)
 - Epigenetics
- Treatment factors (radiation)
 - Total dose, dose/fraction, dose rate, modality (EBRT, brachy), volume of normal tissue
- Other treatments
 - Systemic agents, surgery, OTC stuff patients don't tell you about
- Tumor factors
 - Histology
 - Genetics
 - Epigenetics




Problems With Current Normal Tissue Dose-Volume Guidelines

- Mostly derived from retrospective analyses
- Complications probably under-reported and rarely graded
- May not hold up with very poor organ function (e.g., mean lung dose)
 - No spacial distribution considerations
- Heterogeneous patient populations
 - Co-morbidities, concurrent medications
 - Genetic contributions unknown
- Non-standardized normal tissue contouring guidelines
- Tend to be modality specific
 - Different for SBRT vs types of brachytherapy (LDR vs HDR) vs EBRT
- No clinically accepted biomarkers to help guide dosing decisions



Dose Distribution: EBRT



Tao et al. J Clin Oncol 34: 291, 2015




Dose Distribution: SIRT for Liver Tumors

Fig. 1 Turnoral VOI delineation using MAA SPECT/CT a) CT slide: huge turnor of 12.1×17.4× 9.7 cm with a large part of central necrosis, b) MAA/SPECT CT tumor volume segmentation. Based on MAA SPECT/CT, tumor volume is only 900 cc due to a large part of necrosis. Using CT segmentation, tumor volume is 1310 cc. Doing the hypothesis of absence of radioactivity uptake in necrosis, tumor dose based on MAA segmentation (excluding necrosis volume) is 1.45 fold higher than turnor dose based on CT segmentation (including necrosis volume)



Tumor with large necrotic center

Dose determination varies 45% between CT vs SPECT/CT based calculations





Non-uniform uptake

Garin et al. Eur J Nuc Med Mol Imaging 43: 559, 2016

Tumor vs Normal Tissue Dose Goals: SIRT for Liver Tumors







Kappadath et al IJROBP 102:451, 2018; Chiesa et al. Eur J Nuc Med Mol Imaging 42: 1718, 2015



Choosing the Appropriate Patient Population

- With the exception of Ra223 for selected patients with metastatic prostate cancer, no other alpha emitters are approved for use in patients.
- Current studies using alpha emitters are early phase dose escalation/dose expansion
 - Goal to determine a safe dose to study for effectiveness
- Patients enrolled are those with advanced cancers with few options other than clinical trials
 - Generally used as a monotherapy
 - Patients have limited life expectancy
 - How can you establish safety if late effects are the major concern?



Issues to Consider

- Unlike Ra223, most systemic agents are bound to a carrier, either a small molecule or an antibody designed to preferentially bind to a tumor.
 - Where else in the body is the target protein found?
 - Target proteins occurring in normal tissues will lead to radiation delivery to these tissues producing unwanted side effects
 - Is the binding greater in tumor vs normal tissues?
 - How is the carrier protein handled by the body?
 - Is it excreted through the kidneys or metabolized in the liver?
 - Is it preferentially retained in the tumor vs normal tissues?
 - Will impact on potential AEs



What is Known About Radionuclide Toxicity?

- Acute bone marrow toxicity is common
 - May limit the maximum single dose and the dosing interval
 - Dosing intervals tend to be longer with radiopharmaceuticals than drugs, due to the delayed onset of marrow toxicity and the longer interval for recovery vs many drugs
- Other acute effects depend more on the distribution of binding of the carrier in normal tissues
 - Example: PSMA and dry mouth
- Early phase trials are designed to capture this information
 - Often managed with dose reductions and/or dose interruptions



What Don't We Know About Radiopharmaceutical Toxicities?

- In many cases, we lack long term prospective information on late toxicities
 - Patient populations studied have relatively short life expectancies
 - Requires a commitment to systematic long-term follow-up
 - Will become increasingly important as these agents if these agents are used earlier in the course of a disease
 - Must balance the need for new, effective treatments while at the same time maintaining a commitment to long-term data collection



Future Challenges

- What is the optimal DLT observation period?
 - 30 days? 5 half-lives? Isotope dependent? Linker dependent?
- Is one cycle enough to determine DLTs if multiple cycles are intended?
 - Radiation effects are cumulative
 - May require continuous reassessment trial design
- Treating microscopic vs overt disease
 - Cannot image microscopic disease
 - Dosing may be based purely on normal tissue tolerance
 - Need better guidelines



Conclusions

- An increasing number of radiopharmaceuticals are being studied in patients with advanced cancers
- Owing to their unique method of delivering radiation, these agents hold great promise for the future
- The safe and effective prescribing of these agents will require not only a knowledge of their short-term side effects, but also a better understanding of the long-term risks associated with their use
- Long-term, preferably life-long, follow-up of patients enrolled in prospective trials will be the only way to accurately determine the risk of late complications and truly establish organ-specific tolerance doses





Dosimetry for Radiopharmaceutical Therapy

Donika Plyku, PhD

Medical Physicist, US Food and Drug Administration Division of Imaging and Radiation Medicine (DIRM), Office of Specialty Medicine CDER | US FDA

> FDA-NRC Workshop: Enhancing Development of Targeted Alpha Emitting Radiopharmaceuticals, September 22, 2021





- Radiopharmaceutical Therapy (RPT)
- MIRD Formalism for Internal Radiation Dosimetry
- Dosimetry for RPT
 - Challenges with Alpha Emitters
 - Ac-225

Radiopharmaceutical Therapy (RPT)

- Disseminated Cancer
- Radiation Delivery


www.fda.gov

Kill targeted cells
 by localized
 radiation therapy


Combination of a Radionuclide with a Biologically Active Pharmacophore


- Determines imaging and/or therapeutic properties
- Can also confer desired localization properties (for ex. radio-iodine)

- Overall chemical structure determines
 biological properties
- Acts as a carrier
- Determines localization and bio-distribution



Radiopharmaceutical Therapy (RPT)





External Beam Radiation Therapy (EBRT)



What is important for RPT

- Where does the drug concentrate, and for how long?
 - Biodistribution and/or imaging studies (theranostic approach or image therapeutic agent)

FDA

- What type of radiation is emitted?
 - **Depends on the radionuclide** (β, α-emitter)_A

Radionuclide Emissions

β -Particles


- Elementary particle
- Sparsely ionizing
- Path length ~0.8-10 mm
- 0.2 keV/µm (LOW LET)
- 10³ to 10⁴ tracks to kill cell
- DNA damage is repaired
- Recoil energy: ~10 eV

α -Particles

- He nucleus
- Densely ionizing
- Path length: 50-100 µm
- ~60-240 keV/µm (**HIGH LET**)
- 2-3 tracks kill cell
- Irreparable DNA damage
- Recoil energy: ~100 keV

Photons (γ-rays)

Used for imaging



Milenic et al. Nature Rev. Drug. Disc. 2004, 3, 488

Therapeutic RadionuclidesBeta EmittersAlpha EmittersExamples:Examples:I-131, Y-90, Sm-153,
Lu-177, Sr-89Ra-223, Ac-225, Th-227

FDA-Approved RPTs (Low LET Emitters)

Low LET Emitters	Manufacturer	Indication
I-131 (sodium iodide)	Jubilant Draximage	Treatment of hyperthyroidism, treatment of carcinoma of the thyroid
Y-90 (ibritumomab tiuxetan, Zevalin®)	Spectrum Pharmaceuticals	Treatment of relapsed or refractory, low-grade or follicular B-cell NHL; Treatment of previously untreated follicular NHL
Sm-153 (lexidronam, Quadramet®)	Lantheus Medical Imaging	Relief of bone pain of confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan
Lu-177 DOTATATE (LUTATHERA®)	Novartis/AAA	Therapy for neuroendocrine tumors and other somatostatin receptor expressing tumors
I-131 MIBG (iobenguane [®])		Adult and pediatric patients (12 years and older) w/ iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy
Strontium-89 chloride	GE Healthcare	Relief of bone pain in patients with painful skeletal metastases confirmed prior to therapy
Y-90 loaded glass microspheres	BTG	Treatment of hepatic malignancies
Y-90 loaded resin microspheres	CDH Genetech/Sirtex	Treatment of hepatic malignancies

www.fda.gov

FDA-Approved RPTs (High LET Emitters)

High LET Emitters	Manufacturer	Indication
Ra-223 (Xofigo®)	Bayer Healthcare Pharmaceuticals Inc.	Treatment of patients with castration- resistant PCa, symptomatic bone metastases and no known visceral metastatic disease

Under Development RPT Agents

ClinicalTrials.gov started after 2010, active, recruiting, and completed trials

Review Article | Published: 29 July 2020

Radiopharmaceutical therapy in cancer: clinical advances and challenges

George Sgouros ⊠, Lisa Bodei, Michael R. McDevitt & Jessie R. Nedrow

Nature Reviews Drug Discovery 19, 589–608(2020) Cite this article

Table 2 Selected RPT agents that are on the market or under development

www.fda.gov

	# of trials
Lu-177	70
I-131	80
Cu-67	2
P-32	1
Sm-153	1
Ra-223	81
Ac-225	7
Th-227	4
Pb-212	2
At-211	2

Radiation Dosimetry



U Why do we need to perform radiation dosimetry?

 A measure to predict potential toxicity/efficacy and risk associated with exposure to radiation

Absorbed Dose


- Amount of energy absorbed/mass in target organ/tissue
- \circ Most closely related to the biological effect


Optimal dosing for RPT

• Achieve good tumor response w/o causing normal organ toxicity

The <u>M</u>edical <u>I</u>nternal <u>R</u>adiation <u>D</u>ose (MIRD) Formalism for Internal Radiation Dosimetry

Calculate the energy deposition density (energy absorbed/mass), Absorbed Dose, unit: Gy =





FDA

MIRD Pamphlet #21

www.fda.gov

Time-Activity or Pharmacokinetic (PK) Data



Animal studies – usually performed for the submission of an Investigational New Drug (IND)

- <u>Larger animals (ex. monkeys, dogs)</u> are done by imaging smaller # of animals may be sufficient, 3M & 3F
- <u>Smaller animals (ex. mice, rats) are done by animal sacrifice,</u> sufficient# of animals/time-point, radioactivity is counted (ex. gamma counter) and used to characterize biod.
- Extrapolate to human organ PK data in order to get dose estimate to human organs

Human studies – usually performed in Phase I, II or III of the approval of a New Drug Application (NDA) – involves imaging and/or blood, urine collection

MIRD Absorbed-Fraction Method Image-Based Dosimetry

- 1. Serial quantitative imaging
- 2. Co-registration across time
- 3. ROI (organ, tumor) segmentation
- 4. Model fitting and integration of the time-activity

Ã

 A_0


curve


$$\tilde{A} = \int_{0}^{\infty} A(t) dt \qquad \tau =$$

Time-Integrated Activity Coefficient (TIAC) or Residence Time

$$\begin{array}{c|c} \widetilde{A}_{s} \times \Delta \times \phi_{t \leftarrow s} \\ \hline M_{t} \end{array}$$

www.fda.gov





$$D_{t} = \tilde{A}_{s1} \cdot S(t \leftarrow s1) + \tilde{A}_{s2} \cdot S(t \leftarrow s2) + \dots$$

www.fda.gov

Digital anthropomorphic phantoms of varying size and anatomy, Uni. of Florida

MIRD Absorbed-Fraction Dosimetry Method

- 1. Serial quantitative imaging
- 2. Co-registration across time
- 3. ROI (organ, tumor) segmentation
- 4. Model fitting and integration of the time-activity curve

$$\tilde{A} = \int_{0}^{\infty} A(t)dt$$
 $\tau = \frac{\tilde{A}}{A_0}$ Time-Integrated Activity Coefficient (TIAC)

5. Time-integrated activity to dose conversion

$$D(r_T) = \sum_{r_S} \widetilde{A}(r_S) \cdot S(r_T \leftarrow r_S)$$

OLINDA/EXM, Stabin M.G. et al. JNM, 2005; 46: 1023-7

AUC = Number of decays

t₁=

$$f_{2}$$

Dosimetry Method

MIRD Absorbed Fraction Dosimetry

- Dosimetry for risk evaluation of diagnostic RPs
- Stochastic effects
- Reference anatomy: representative of a population, not patient-specific)
- Tumor dosimetry: assume spheres
- Activity-based calculation

A _{source}	S _(t←s)	D _(t←s)
Group of patients/healthy volunteers or extrapolated from animals	Model ± adjusted	Model ± realistic

In the Context of Therapy

Modify phantom organ masses based on organ volume identified on patient's CT

$$S(pt) = S(model)x \frac{Organ Mass(model)}{Organ Mass(pt)}$$

FDA

Dosimetry Method

Voxelwise Method


- Organ toxicity/efficacy, tumor response
- Deterministic effects
- Patient-specific dosimetry appropriate for RPT
- Dose-rate based calculation using Monte-Carlo
- Model voxel-level energy deposition for actual patient anatomy including tumors
- Can incorporate radiobiology (ex. calculate BED, EUD)

 Table Dosimetry Platforms That Have Received 510(k) Clearance From the U.S. Food and Drug Administration, as of February 2020

Dosimetry Platform	510(k) Clearance Date	Dosimetry Method
OLINDA/EXM v1.0 ²⁷	June, 2004	Absorbed Fraction
Hermes OLINDA/EXM v2.0	July, 2017	Absorbed Fraction
MIM SurePlan MRT	January, 2019	Voxelwise – Convolution
DOSIsoft PLANET Dose	March, 2019	Voxelwise – Convolution
Hermes Voxel Dosimetry	October, 2019	Voxelwise – Monte Carlo

www.fda.gov

α-Particle Emitting Radionuclides



Criteria for α-Emitters:


- Half-life and decay pathway,
- Large fraction of alpha emissions per decay,
- High energy photon emissions,
- Availability in high purity, cost of production, biological and chemical stability.



- Potential for therapeutic use:
 - ²²⁵Ac, ²¹²Bi, ²¹³Bi, ²¹¹At, ²¹²Pb, ²²³Ra, ²²⁷Th
- In 1997 ²¹³Bi: The first alpha emitter to be used in clinical trials for therapy
 - 213Bi: short half-life (45.6 min), decays with a 440 keV gamma ray - ideal for imaging
 - In 2013 ²²³Ra: The first FDA- approved radionuclide for the treatment of patients with castration-resistant PCa, with symptomatic bone metastases
 - ²²³Ra: long half-life (11.4 days), decays with four alpha emissions

Actinium-225 (Ac-225)

- 4 high energy alpha particles/decay
- Easily chelated to DOTA and other chelating agents
- Half-life: 10 days, $E_{\alpha-max} = 6-8$ MeV (23 MeV of energy overall)
- Available from ORNL
- Currently being used in a variety of preclinical and clinical trials




Dosimetry for α-Emitters

PK Fate of Daughter Nuclides

- AD estimates depend on the PK fate of unstable daughters
- Consider the half-life, biod. of daughters and radiosensitivity of organs
- Recoil energy: ~100 keV (α) vs.
 ~10 eV (β) Bond broken with agent
- If imaging is not possible use biokinetic modeling to obtain time-activity curves

www.fda.gov



PK model for radiolabeled antibody – to derive kinetics of antibody-bound radionuclides Sgouros, et al. JNM, 1993. 34(3): p. 422-30

Imaging of α-Emitting Radioisotopes

Seo, Y. (2019). NMMI, 53(3), 182-188.

Ghaly, M., et al. (2019). JNM, 60(supplement 1), 41-41.


Ghaly, M., et al. (2017), In *EJNMMI* (Vol. 44, pp. S180-S180).

Ghaly, M., et al.(2017). JNM, 58(supplement 1), 748-748.

Dosimetry for α-Emitters

LET ~ 300-1200x higher than β -emitter Relative Biological Effectiveness (**RBE**), RBE~3-7 but depends on AD, biological endpoint, tissue type

 $RBE(x) = \frac{D_r(x)}{D_r(x)}$ -> x-rays, γ -rays, β -particles -> test radiation



RBE Value - MIRD Pamphlet #22

- Based on a review of experimental literature, an RBE value between 3-5 was recommended for cell killing by a panel convened by the DOE in 1996 (Feinendegen et al. Radiat. Res. 1997; 148: 195-201)
- **RBE = 5** was recommended for projecting the possible deterministic biologic effects associated with an estimated α -particle absorbed dose.
- **RBE = 5** accounts for the difference in biological effects of alpha-particle vs external beam irradiation. 20

Dosimetry for α-Emitters

FDA


Range ~100 µm vs few mm

Dosimetry method should account for both **organ-level** and **micro-scale** distributions (range is 50-100 μm)

- Organ-Level: Patient-imaging
- Micro-scale: Combine wholeorgan measurements with preclinical measurements – μscale biod./PK data in subregions of critical organs

www.fda.gov

Hobbs et al. PMB (2012) Small-scale dosimetry



Implement in the context of the MIRD methodology MIRD Pamphlet #22

Summary

- RPT is a systemic and targeted treatment modality for disseminated cancer.
- Dosimetry for RPT has its roots in the formalism established by the MIRD Committee to assess radiation risk for diagnostic radiopharmaceuticals.
- A more appropriate dosimetry scheme for RPT involves a more patient-specific approach, voxelized calculations and tumor dosimetry.
- Dosimetry for alpha emitters includes other special considerations: RBE value, micro-scale dosimetry.
- Pre-clinical and clinical dosimetry studies in general are essential for the development of new radiopharmaceuticals for RPT.



Thank You!

www.fda.gov




Additional Slides

Accelerator Produced Ac-225

Accelerator-produced Ac-225 (BNL, LANL, ORNL) -> ~0.12% Ac-227 (half-life 218 years) impurity in the final product

- Both Ac-225 and Ac-227 are α-emitters daughters may become unconjugated during decay
- Ac-225: Daughter products decay in the same location as parent - However, re-distribution of **free Bi-213** to the kidneys can more than double the dose to kidneys (Schwartz 2011)
- Ac-227: Fr-223 (1.4%, 22 min) and Th-227 (98.6%, 18.7 days) -> Ra-223 (11.4 days) - Free Th-227 and Ra-223 may accumulate in bone.
- Different scenarios can be considered: free and bound for Ac-225 and Ac-227 and daughters
- Biod. data for Ac-225 may be collected using surrogate imaging (In-111) assume Ac-225 and Ac-227 remain bound
- ICRP bio-kinetic models for free radionuclides scenario
- Highest impact in added risk due to Ac-227 presence is when Th-227 becomes unconjugated.





1

Dosimetry of alpha emitter: and caution for extravasation.

Kish Chakrabarti, Ph.D., FAAPM DIRM/OND/CDER



Overview

• Radium-223 dichloride Castration-resistant prostate cancer in patients with bone metastases: FDA Approved alpha emitter

Outline:

Discuss Dose calculations procedure provided by the sponsor :

- Pharmacokinetics: Glenn Flux
- Dosimetry: Sgouros

Extravasations from alpha emitters


Table 1.



Decay chain for radium-223 (²²³Ra). The relative proportions of the branched decay from bismuth-211 (²¹¹Bi) are 0.997 and 0.003 for ²¹¹Bi \rightarrow thallium-207 (²⁰⁷Tl) and ²¹¹Bi \rightarrow polonium-211 (²¹¹Po), respectively

Radionuclide	Mode of decay	Abundance	Half-life
$^{223}\mathrm{Ra}\!\rightarrow\!^{219}\mathrm{Rn}$	α	100%	11.43 days
$^{219}\mathrm{Rn}{\rightarrow}^{215}\mathrm{Po}$	α	100%	3.96 s
$^{215}\text{Po} \rightarrow ^{211}\text{Pb}$	α	100%	1.78 ms
211 Pb \rightarrow 211 Bi	β	100%	36.1 min
$^{211}\text{Bi} \!\rightarrow\! ^{211}\text{Po}$	β-	0.276%	2.14 min
$^{211}\text{Bi}\!\rightarrow\!{}^{207}\text{Tl}$	α	99.72%	2.14 min
211 Po \rightarrow 207 Pb	α	100%	0.516 s
$^{207}\text{Tl}\!\rightarrow\!^{207}\text{Pb}$	β-	100%	4.77 min
207 Pb \rightarrow -	Stable		-

²⁰⁷Pb, lead-207; ²¹¹Pb, lead-211; ²¹⁹Rn, radon-219.





Radioactive Properties of Radium-223

- Radium-223 (223Ra) is a natural bone-seeking alpha emitter with high linear energy transfers (LET **80 keV/micrometer**) leads to a high frequency of double-strand DNA breaks in adjacent cells, resulting in an anti-tumor effect on bone metastases.
- The alpha particle range from radium-223 dichloride is less than 100 micrometers (less than 10 cell diameters) which limits damage to the surrounding normal tissue.
- There are 5 alpha, 3 electron, 18 photons (12 gamma and 6 x-ray) emissions in the process.

FDA

Radioactive Properties of Radium-223

- Ra-Dichloride clears quickly from the blood, with only 1.1% of administered activity remaining in the blood after 24 hours and a large amount (61% at 4 hours) taken up in the skeleton.
- Radium-223 decays in six steps via a chain of alpha and beta emissions into stable lead, ²⁰⁷Pb. The total amount of emitted energy per 223Ra-decay is 28.2 MeV.

L/

• 223 Ra $\rightarrow ^{219}$ Rn $\rightarrow ^{215}$ Po $\rightarrow PB \rightarrow ^{211}$ Bi $\rightarrow ^{207}$ TI $\rightarrow ^{207}$ PB (stable)


7

²¹¹Po

Detection and Imaging Challenges of Ra-223




- ²²³Ra undergoes a complicated decay scheme, with a series of six daughter products, before decaying to stable lead. The total emitted energy is 28.2 MeV, of which 95% is from alpha emissions, 3.2% from beta particles and <2% from gamma emissions.
- This results in a low signal which can present challenges for quantitative imaging, but nevertheless, introduces the potential for individualized biodistribution studies.
- Imaging characteristics for ²²³Ra, identifying three energy peaks as suitable for imaging of the 10 photon energies emitted with a probability >1%.
- Optimal energy windows were set at 82, 154 and 270 keV, each with a 20% width. Camera sensitivity was found to be 69, 31 and 34 counts per second (cps) MBq⁻¹ from the three windows, respectively.



www.fda.gov





Anterior scans of radium-223 at days 0, 1, 2, 3 and 6 following administration of 55 kBq/kg. The study confirmed that activity was quickly cleared Ref. Glen Flux

Experimental:

• Mean absorbed radiation doses in major organs were calculated based on clinical and biodistribution data in **five patients with castration-resistant prostate cancer**

• Although whole-body dosimetry can be assessed from either whole-body scans or from external retention measurements, dosimetry for red marrow can be obtained from imaging and from blood sampling and should take into account the activity in the extracellular fluid, the blood, the bone marrow cells, the bone and major organs of uptake.

Patient data acquisition several detailed processes and equipment:

- 2 mm arc with NaI detector used in six different energy ranges 37 keV-890 keV. Whole-body measurements were performed
- Gamma spectroscopy of samples of urine and feces using a whole body counter
- Sample counter for all blood and samples counting using automatic gamma counter
- Gamma camera imaging in the energy range 74 keV to 284 keV

These provided Imaging, blood samples, excretion products and activity quantification

The study confirmed that activity was quickly cleared from the blood.

Theoretical Model and Calculations:

- FDA
- The absorbed doses in normal organs were calculated using the OLINDA-EXM software (Organ Level Internal Dose Assessment/Exponential Modeling), however the OLINDA-EXM program has been designed for use with established radionuclides, all of which are beta- and gammaemitters i.e. long range particles. It is not yet adapted to the very short radiation range of alpha-emitters, and additional assumptions have been made to provide the best possible dosimetry calculations.
- The dosimetry calculations are performed using **the biodistribution data by Glenn Flux** an internal report from the sponsor.
- Calculations of absorbed **radiation doses were performed Sgouros** using OLINDA reported through an internal report from the sponsor.

- Absorbed dose calculations were performed using the MIRD Committee S-value based method as described in pamphlet 21.
- The cumulative activity CA (MBq x h) in the source organs was derived from the whole body patient scans for all organs with quantifiable amounts of activity in the images.
- Residence time (MBq x h/MBq) is the is the input data for OLINDA-EXM program (OLINDA).
- an alpha particle-emitter, assumptions were made for intestine, red marrow and bone/osteogenic cells to provide the best possible absorbed radiation dose calculations, considering its observed biodistribution and specific characteristics. Additional particular modeling was applied for the lungs.

The absorbed dose to the lungs is estimated as the dose contribution from ²²³Ra and daughter decays in the blood-containing fraction of the lung mass and also the dose contribution from ²¹⁹Rn and daughter decays in the respiratory tract.

Absorbed dose calculations(contd.)

The absorbed dose to all organs except for GI (incl. small and large intestines), RM, bone/osteogenic cells, and HW was obtained using OLINDA. Since the daughters have been confirmed, in preclinical and clinical studies, to decay at the site of parent decay, the residence time for ²²³Ra was applied to all of the daughters and a separate OLINDA calculation was performed for each daughter. The resulting absorbed doses were weighted to reflect the yield of each daughter in the ²²³Ra decay scheme, and summed to provide the total absorbed dose.

Details regarding the GI, RM, bone/osteogenic cells, and HW calculations are provided by Sgouros.

Table 1: Absorbed Radiation Doses per

Administered Activity and Accumulated Dose

Organ	Mean (mGy/MBq)	Mean (rad/mCi)	Coefficient of variation	Absorbed dose+	Accumulated
			(%)	(Gy)	absorbed dose ⁺⁺ (Gy)
Osteogenic cells	1152	4263	41	4.61	28
Red marrow	139	514	41	.556	3.34
LLI wall [*]	46	172	83	.184	1.10
Colon*	38	142	56	.152	.912
ULI wall*	32	120	50	.128	.768
Small intestine wall	7.3	27	45	.029	.174
Urinary bladder wall	4.0	15	63	.0160	.096
Kidneys	3.2	12	36	.013	.0780
Liver	3.0	11	36	.0123	.0738
Heart wall	1.7	6.4	42	.0068	.0400
Lungs	1.2	4.5	48	.0048	.0290
Ovaries	0.49	1.8	40	.00196	.018
Uterus	0.26	0.94	28	.001	.006
Gallbladder wall	0.23	0.85	14	.00092	.00552
Stomach wall	0.14	0.51	22	.00056	.0034
Adrenals	0.12	0.44	56	.00048	.0030
Muscle	0.12	0.44	41	.00048	.0030
Pancreas	0.11	0.41	43	.00044	.00264
Brain	0.10	.37	80	.00040	.00240
Spleen	0.09	.33	54	.00036	.0022
Testes	0.08	.31	59	.00032	.0021
Skin	0.07	.27	79	.00028	.00168
Thyroid	0.07	.26	96	.00028	.00168
Thymus	0.06	.21	109	.00024	.00144
Breasts	0.05	.18	120	.00020	.00120
Whole body	23	86	16	.092	.552

Adapted from the table in labelling where RBE value of 1 is used


Calculated absorbed radiation doses :

- The major radiation dose is to the **osteogenic cells** on bone surfaces as associated with bone metastases. The highest absorbed doses were calculated in the bone (osteogenic cells) (4.75 Gy for single and; 28.5 Gy after 6 administrations) and **the red marrow, which received an absorbed dose of 0.573 Gy**, for a single administration assuming repair takes place within the administration interval.
- As shown on table 1, the lung absorbed dose for a 73-kg adult male receiving 55 kBq/kg 223Ra is 4.9 mGy (with accumulated absorbed dose of 2.4 after 6 administration), with range (2.8 Gy to 7.2 Gy) (2) still far below the 17.50 Gy level at which lung toxicity is seen following whole lung irradiation at 2000 mGy/fraction.

Estimates of the threshold doses for morbidity* or mortality in adults exposed to acute, fractionated or protracted, and chronic irradiation. The values are generated from ICRP 118 (9) Table 2

Organ	1%: morbidity Associated with disease	Time to death or organ failure	Threshold absorbed dose (Gy) for 1% rate mortality or organ failure
Bone Fracture		>1 year	25 in 2 Gy fraction
Red Marrow	Depression of hematopoiesis in 3-7 days; possible H-ARS mortality in 30-60 days ^b		10-14
Lungs	Pnumonitis mortality	1-7 months	17.5

Relative Biological Effectiveness (RBE), RBE~3-7 but depends on AD, biological endpoint, tissue type as discussed by Donika Plyku, PhD





Absorbed dose vs Effective dose

The absorbed dose values presented in this report are expressed in Gy and not as effective doses in Sv. Although effective dose can be calculated, it does not apply to the therapeutic use of alpha-particle-emitting radiopharmaceuticals. A detailed explanation for this is provided in MIRD Pamphlet 21 and in the MIRD Committee's monograph on alpha-particle dosimetry





Extravasation: Usual acute signs and symptoms

- pain,
- erythema,
- swelling,
- Compartmental syndrome
- local blistering (indicative of at least a partial-thickness skin injury),
- mottling/darkening of skin,
- ulceration (usually not evident until 1-2 weeks after injury),
- NOTE Extravasation can be asymptomatic

Other clinical consequences

- Loss of diagnostic or therapeutic efficacy
- Delayed reactions
 - Ulceration, fibrosis

Extravasation:



- The primary effect to the surrounding tissue can be attributed to nonpenetrating emissions, e.g. soft X-rays (10Kev).
- Extravasation of diagnostic radiopharmaceuticals is common. 99mTc, 123I, 18F, and 68Ga, purely β emitters do not require specific intervention
- Extravasation of therapeutic radiopharmaceuticals can give severe soft tissue lesions.
- Although not evidence based, surgical intervention should be considered. Dosimetry and follow up is advised.
- Pharmaceutical intervention has no place yet in the immediate care of radiopharmaceutical extravasation



Extravasation from Alpha emitter

• Cutaneous squamous cell carcinoma should be recognized as a rare but potential adverse event following cutaneous extravasation of radium-223 and is likely a side effect that is severely underreported. Katie E. Benjegerdes el alroc (Bayl Univ Med Cent) 2017;30(1):78-79

Summary:



- We have discussed Radium-223 the sole alpha radionuclide approved by the FDA.
- Alpha emitters rapidly and increasingly finding use in nuclear medicine
- Want of proper imaging technology makes it very difficult to estimate absorbed organ doses
- Determination of proper RBE is also an important issue
- Extravasation incidents are still a few and far between. FDA continues to monitor through its post marketing reporting system